Reza Abdi, M.D., has a reason to care about diabetes research—he has a father and a brother with the disease. Dr. Abdi, of Brigham and Women’s Hospital in Boston, is an expert in immune therapy research, specifically nanotechnologies—miniscule therapies that can deliver immune treatments to specific regions in the body. His goal: To bring new therapies to people with type 1 diabetes (T1D).
“Immunotherapy represents probably the most promising routes or ways of treating type 1 diabetes.”
– Reza Abdi, M.D., Brigham and Women’s Hospital
Please join us for an inside look, as we present the fifth video in our seven-part series Inside the Lab at Boston. See as Dr. Abdi gives a first-hand overview of the passion, the obstacles and the hope that immune therapies may have for the T1D community, and how he and JDRF are helping to advance.
If you haven’t seen the other featured videos in this series already, don’t miss out. See how scientists are collaborating to expedite the process of finding cures:
- Boston: A Global Leader of Type 1 Diabetes Research is an overview of the leading scientists and institutions for T1D investigations in Boston and JDRF’s role in shaping and supporting this research.
- Beta Cell Therapies: Replacement Research in Boston looks at the collaborations and skills that researchers in Boston are using to tackle the complex task of replacing beta cells in people with T1D.
- Beta Cell Therapies: Regeneration Research in Boston asks: Can we internally regenerate and protect existing beta cells, and therefore find cures for T1D?
- Immune Therapies: Prevention Research in Boston shows experts that are working to delay T1D, or stop it before it starts.
Don’t forget to check back next week, when we highlight Kidney Complications Research in Boston, featuring Monika Niewczas, M.D., Ph.D., M.P.H., and Manoj Gupta, Ph.D. A week later, be on the lookout for Eye Complications Research in Boston, featuring Jennifer Sun, M.D., M.P.H.
Funding immune therapy research is one of JDRF’s most critical undertakings, essential in our mission to find cures for T1D. Please consider donating today, and we’ll turn Type 1 into Type None, with your support.